SOURCE: Monaghan Medical Corporation

Monaghan Medical Corporation

October 28, 2014 14:56 ET

Monaghan Medical Presents Poster Revealing Possible Under-Dosing by Continuous Nebulizers at Varying Breathing Patterns

PLATTSBURGH, NY--(Marketwired - October 28, 2014) - Monaghan Medical announced today that the following study data will be presented during the American College of Chest Physicians Annual Conference in Austin, Texas, October 25 through October 30, 2014. The data will be presented via oral and poster presentations as follows:

Monaghan Medical and its affiliate, Trudell Medical International, collaborated on a study to demonstrate that under-dosing of inhaled medication delivered by continuous nebulizers is possible as the result of changes to inspiratory / expiratory (I/E) ratio. The purpose of the study was to demonstrate the likely variability of medication delivery from continuously operating pneumatic nebulizers at different I/E ratios in tidal-breathing patients.

The study was conducted with two continuously operating jet nebulizers, AirLife† Misty Fast†, by CareFusion and NebuTech† HDN† by Salter Labs. Each nebulizer was evaluated in a simulation of adult tidal breathing on an ASL5000 breathing simulator by IngMar Medical. The simulator was coupled with a mouthpiece and the following waveforms were investigated: tidal volume fixed at 500ml, I/E ratios equal to 1:1, 1:2, 1:3 and 1:4, breathing cycles/min equal to 15, 10, 7 and 6 respectively. 

The emitted aerosol from the nebulizer, containing albuterol sulfate medication, was collected at the bacterial/viral filter, mimicking the entry to the oropharynx. Each nebulizer was tested with 2.5mg albuterol sulfate in a 3-mL fill. The total mass of albuterol was calculated after assaying for albuterol by a validated HPLC-based procedure. 

In parallel experiments, fine droplet fraction < 4.7 micrograms were determined by laser diffractometry on the Malvern Spraytec laser diffractometer. 

The study results showed that fine droplet mass values decreased with increasing I/E ratio for both nebulizer groups. The decline across the range studied taking I/E ratio equal to 1:1 as reference was -42% for the Misty Fast† and -46% for the HDN nebulizer. 

This study concludes that significantly less medication was delivered per treatment by both the AirLife† Misty Fast† and NebuTech† HDN† with changes to patient inspiratory / expiratory (I/E) ratio. The increasing proportion of each cycle devoted to exhalation results in an increase of medication being wasted by these continuously operating nebulizers. Additionally, changes in a patient's inspiratory / expiratory (I/E) ratio is a likely clinical scenario as disease state worsens or in patients with a compromised respiratory condition. One potential solution to this clinical challenge would be the use of a breath-actuated nebulizer, such as the AeroEclipse® II Breath Actuated Nebulizer (BAN)

The AeroEclipse® II BAN creates aerosol in response to the patient's inspiratory flow. This patient on-demand therapy means less medication waste, higher drug delivery efficiency and safer clinician working environments.

"The AeroEclipse® II BAN consistently delivers a reliable dose of medication, regardless of patient I:E ratio," states Dominic Coppolo, Vice President of Clinical Affairs at Monaghan Medical Corporation. "The clinician cannot control how a patient breathes during a nebulizer treatment, but more of the medication is available to the patient because of minimal loss of aerosol to the environment," Coppolo concludes. 

The American College of Chest Physicians is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research, and team-based care. The poster will be presented at CHEST on Wednesday, October 29th. For an informational video and a copy of the poster, please visit

Monaghan Medical Corporation
 (MMC), headquartered in Plattsburgh, New York (USA), is a leader in the development, manufacture and marketing of respiratory devices, from the flagship AeroChamber® Brand of Valved Holding Chamber (VHC) to the latest state-of-the-art Aerobika® OPEP therapy. These devices are supported by peer reviewed and published studies.

† trademarks and registered trademarks of the respective companies

Contact Information